Trial Design
Trial Design FIRST phase 3 trial leading to an approval specifically for HER+/HER2- aBC patients with a PIK3CA mutation 1,2 SOLAR-1 Study Design 1,2 Randomized, double-blind, placebo-controlled, multicenter phase 3 trial in HR+/HER2- aBC 1,2 A total of...